Seven Strategic Cooperation with Thermo Fisher Scientific from 2021 to Present

In recent years, local governments have made great efforts to build biomedical industrial parks, relying on first-class industrial supporting services and excellent ecological innovation vitality to build biomedical demonstration sites, attracting long-term investment from many foreign and domestic companies. From January to the end of July 2021, Thermo Fisher Scientific launched seven strategic cooperation with local Chinese institutions, covering innovative technologies and solutions in the fields of pharmaceuticals, analytical testing, mass spectrometry technology, biomedical industry whole-industry chain service capabilities, laboratories, informatization management, life science research and development center, life science industry base and other aspects. Thermo Fisher Scientific has launched a more comprehensive strategic cooperation.

The First Cooperation: Strategic cooperation between Thermo Fisher Scientific and JW Therapeutics in Shanghai

On February 3, 2021, Thermo Fisher Scientific and JW Therapeutic reached a strategic cooperation on the non-exclusive commercial use rights of Thermo Fisher's Gibco™ CTS™ Dynabeads™ CD3/CD28 magnetic beads in Shanghai. The cooperation will further promote the clinical development and commercialization of leading CAR-T therapies (chimeric antigen receptor T-cell immunotherapy) in China, such as JW Therapeutic’s flagship product, Recchio-cel ("relma-cel") Production. CTS Dynabeads magnetic beads are one of Thermo Fisher’s proven CTS (Cell Therapy System) series of products, which integrates product solutions from cell separation and activation, gene transduction, to cell expansion in order to solve the challenges faced in the production process.

The Second Cooperation: Strategic cooperation between Thermo Fisher Scientific and China Association for Instrumental Analysis -- University Analysis and Testing in Shanghai

On March 19, 2021, Thermo Fisher Scientific and the China Association for Instrumental Analysis -- University Analysis and Testing （ATCTEST） signed a strategic cooperation agreement at the Shanghai Thermo Fisher China Customer Experience Center. The cooperation will rely on Thermo Fisher’s innovative technology and solutions in the field of analysis and testing, combined with research results of ATCTEST and the platform resource network. The cooperation can also promote school-enterprise cooperation and share cutting-edge measures through the creation of a live exchange platform and the establishment of professional innovation awards, and create a first-class university analysis and testing researcher exchange, cooperation, innovation, and development platform.

The Third Cooperation: Strategic cooperation between Thermo Fisher Scientific and Medicalsystem Biotechnology Co., Ltd. in Ningbo

On March 26, 2021, Thermo Fisher Scientific and Medicalsystem Biotechnology signed a strategic cooperation agreement in Ningbo. Based on its own advantages in advanced manufacturing, cutting-edge R&D and professional services, Thermo Fisher Scientific will work with Medicalsystem Biotechnology to jointly promote the whole-process integration strategy of mass spectrometry technology in the field of clinical testing, accelerate the localization of clinical mass spectrometry technology in multiple dimensions, to facilitate the clinical application of high-quality, multi-level mass spectrometry solutions, and to create a complete ecological chain of clinical mass spectrometry.

The Fourth Cooperation: Strategic cooperation between Thermo Fisher Scientific and Beijing Xinshengchao Biotech in Beijing

On April 29, 2021, Thermo Fisher Scientific and Beijing Xinshengchao Biotech signed a strategic cooperation agreement. This cooperation aims to build Beijing Xinshengchao Biotech and its Zhong Guan Cun Science Park into a leading open and professional high-end shared innovation platform for biomedicine research and development at home and abroad, and an incubator for biomedical innovative talent project "Incubator + Accelerator". In the planning of the first phase of the project, the two parties plan to jointly build a basic experimental platform, including six components: public experimental platform, molecular biology platform, cell culture platform, drug analysis platform, protein purification platform and digital operation plan platform.

The Fifth Cooperation: Strategic cooperation between Thermo Fisher Scientific and Chengdu Tianfu International Bio-town in Chengdu

On May 25, 2021, Thermo Fisher Scientific and Chengdu Tianfu International Bio-town jointly build the "Thermo Fishery-International Biological City Joint Innovation Laboratory" positioned as an "incubator + public technology platform" for the biomedical industry.

The cooperation will aim at providing industrial innovation platforms and operation management services with safety guarantees and standardized management for the enterprises in the Bio-tech, and will cooperate in the construction of laboratory information system and asset management. In addition, a centralized procurement platform will be built to reduce corporate procurement and operating costs, so that companies can be developing rapidly.

The Sixth Cooperation: Thermo Fisher Scientific China Life Science R&D Center in Suzhou

On May 27, 2021，Thermo Fisher Scientific and Suzhou Industrial Park Administrative Committee signed a strategic cooperation to invest in the establishment of Thermo Fisher Scientific China Life Science R&D Center in China, which will assist Thermo Fisher in accelerating research results of life sciences.

The Seventh Cooperation: Thermo Fisher Scientific China Life Science Industry Base in Suzhou

On July 28, 2021, Thermo Fisher Scientific and Suzhou New District signed a cooperation, announcing that it will invest in the construction of another new base in Suzhou New District. The new base will produce in vitro diagnostics and biopharmaceutical-related products. After completion, it will become Thermo Fisher's largest life science industry base in the Asia-Pacific region. Thermo Fisher's total investment this time amounts to 50 million U.S. dollars, which is expected to be completed and put into use in 2022.

Recently, Professor Song Haibo, vice chairman of the National Association of Health Industry and Enterprises Management, chairman of the China Association of In Vitro Diagnostics, published “IVD Industry Overview and Thoughts on Future Development” stated: "In recent years, foreign companies have deployed localized production and research and development of products, which indicates that the domestic layout, acquisition and strategic cooperation of international companies are continuously accelerating. The epidemic is bound to further promote international companies through the above methods to accelerate the pace of localized production R&D investment and acquisitions.”In conclusion, Thermo Fisher Scientific’s performance in the first half of 2021 has proved this view with facts.